Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19014047 | 0.79 | KMT2A (0.51) | OPRM1ALDH1A1KMT2A | |
| SCHEMBL23032767 | 0.79 | OPRM1 (0.49) | OPRM1DRD4SIGMAR1ALDH1A1BCHE | |
| SCHEMBL22578859 | 0.79 | OPRM1 (0.49) | OPRM1DRD4SIGMAR1ALDH1A1BCHE | |
| SCHEMBL7245601 | 0.78 | DRD2 (0.49) | OPRM1DRD4KMT2AOPRD1OPRK1 | |
| SCHEMBL2178280 | 0.77 | OPRM1 (0.60) | OPRM1SIGMAR1OPRD1OPRK1 | |
| SCHEMBL6618877 | 0.75 | DRD4 (0.54) | OPRM1DRD4SIGMAR1ALDH1A1BCHE | |
| SCHEMBL1022483 | 0.75 | OPRM1 (0.54) | OPRM1DRD4SIGMAR1ACHEFUCA1 | |
| SCHEMBL21071714 | 0.74 | OPRM1 (0.82) | OPRM1DRD4ACHEOPRD1OPRK1 | |
| SCHEMBL21142567 | 0.74 | OPRM1 (0.82) | OPRM1DRD4ACHEOPRD1OPRK1 | |
| SCHEMBL6619688 | 0.73 | OPRM1 (0.51) | OPRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | claimed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1178048-B1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6552015-B2 | Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | disclosed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | PFIZER PRODUCTS INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1178048-A1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | CNR1, CBR1, CLIC1 | OPRM1 143/4885DRD4 1043/4885SIGMAR1 174/4885 |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | HTR5A, HTR1A, HTR2A | OPRM1 71/4885DRD4 385/4885SIGMAR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.